No black box warning on record for Erlotinib

As of the latest FDA labeling reviewed, Erlotinib (ERLOTINIB HYDROCHLORIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Erlotinib medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Interstitial lung disease (ILD) : Occurs in 1.1% of patients. Withhold erlotinib tablets for acute onset of new or progressive unexplained pulmonary symptoms, such as dyspnea, cough and fever. Discontinue erlotinib if ILD is diagnosed. ( 5.1 ) Renal failure : Monitor renal function and electrolytes, particularly in patients at risk of dehydration. Withhold erlotinib tabl

No black box warning on record for Erlotinib

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Interstitial lung disease (ILD) : Occurs in 1.1% of patients. Withhold erlotinib tablets for acute onset of new or progressive unexplained pulmonary symptoms, such as dyspnea, cough and fever. Discontinue erlotinib if ILD is diagnosed. ( 5.1 ) Renal failure : Monitor renal function and electrolytes, particularly in patients at risk of dehydration. Withhold erlotinib tabl

Erlotinib Black Box Warning

No black box warning on record for Erlotinib

Other warnings & precautions

Erlotinib Black Box Warning

No black box warning on record for Erlotinib

Other warnings & precautions